SG11201901633WA - 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection - Google Patents
7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infectionInfo
- Publication number
- SG11201901633WA SG11201901633WA SG11201901633WA SG11201901633WA SG11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA SG 11201901633W A SG11201901633W A SG 11201901633WA
- Authority
- SG
- Singapore
- Prior art keywords
- shanghai
- building
- international
- road
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIP0 I PCT omit VIII °nolo 010 0111011101111101 ow (10) International Publication Number WO 2018/041763 Al (51) International Patent Classification: CO7D 473/24 (2006.01) A61P 31/00 (2006.01) A61K 31/522 (2006.01) (21) International Application Number: PCT/EP2017/071514 (22) International Filing Date: 28 August 2017 (28.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2016/097140 29 August 2016 (29.08.2016) CN PCT/CN2017/092653 12 July 2017 (12.07.2017) CN (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: GAO, Lu; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). LIANG, Chungen; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). YUN, Hongy- ing; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). ZHENG, Xiufang; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). WANG, Jianping; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). MIAO, Kun; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). ZHANG, Bo; Building 5, No. 720, Cailun Road, Shanghai 201203 (CN). (74) Agent: BERNARD, Guillaume; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF It VIRUS INFECTION (57) : The present invention relates to compounds of formula (I), wherein R 1 , R and 2 N 0 NH 2 HN I 11 \":; z . / 0=S R 1 N R2 O 00 O C R 3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as TLR7 agonists for the treatment of viral infections. 0
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016097140 | 2016-08-29 | ||
| CN2017092653 | 2017-07-12 | ||
| PCT/EP2017/071514 WO2018041763A1 (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901633WA true SG11201901633WA (en) | 2019-03-28 |
Family
ID=59738346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010520SA SG10202010520SA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| SG11201901633WA SG11201901633WA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202010520SA SG10202010520SA (en) | 2016-08-29 | 2017-08-28 | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10233184B2 (en) |
| EP (2) | EP3865482A1 (en) |
| JP (2) | JP7013467B2 (en) |
| KR (2) | KR102459155B1 (en) |
| CN (1) | CN109641904B (en) |
| AU (3) | AU2017320742B2 (en) |
| BR (1) | BR112019003519A2 (en) |
| CA (1) | CA3034148A1 (en) |
| CL (1) | CL2019000512A1 (en) |
| CO (1) | CO2019000932A2 (en) |
| CR (1) | CR20190087A (en) |
| DK (1) | DK3504210T3 (en) |
| ES (1) | ES2867849T3 (en) |
| HR (1) | HRP20210621T1 (en) |
| HU (1) | HUE053944T2 (en) |
| IL (3) | IL293475A (en) |
| MA (1) | MA46038B1 (en) |
| MX (2) | MX2019002129A (en) |
| MY (1) | MY197408A (en) |
| PE (1) | PE20190476A1 (en) |
| PH (1) | PH12019500432A1 (en) |
| PL (1) | PL3504210T3 (en) |
| PT (1) | PT3504210T (en) |
| RS (1) | RS61752B1 (en) |
| RU (1) | RU2751349C2 (en) |
| SG (2) | SG10202010520SA (en) |
| SI (1) | SI3504210T1 (en) |
| TW (1) | TWI671300B (en) |
| UA (1) | UA124270C2 (en) |
| WO (1) | WO2018041763A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045906T2 (en) * | 2015-05-08 | 2020-01-28 | Hoffmann La Roche | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| ES2867849T3 (en) * | 2016-08-29 | 2021-10-21 | Hoffmann La Roche | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of viral infection |
| CN109715214B (en) * | 2016-09-13 | 2022-03-04 | 豪夫迈·罗氏有限公司 | Combination therapy of a TLR7 agonist and an HBV capsid assembly inhibitor |
| CN111699187A (en) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | Novel sulfone compounds and derivatives for the treatment and prevention of viral infections |
| CN111801100B (en) * | 2018-02-28 | 2023-10-24 | 豪夫迈·罗氏有限公司 | 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer |
| WO2020056008A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
| WO2020162705A1 (en) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CA3170551A1 (en) | 2020-03-02 | 2021-09-10 | Yong Taik Lim | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
| CN116056725A (en) | 2020-08-04 | 2023-05-02 | 蛋白科技先鋒 | Conjugate of a functional drug with temporarily inactivated active site and Toll-like receptor 7 or 8 agonist and use thereof |
| JP2023536945A (en) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | Kinetic Adjuvant Ensemble |
| EP4194006A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| CN114315861A (en) * | 2020-09-27 | 2022-04-12 | 上海维申医药有限公司 | Macrocyclic TLR7 agonist, preparation method thereof, pharmaceutical composition and application thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0141927B1 (en) * | 1983-08-18 | 1991-10-30 | Beecham Group Plc | Antiviral guanine derivatives |
| TW552261B (en) | 1996-07-03 | 2003-09-11 | Japan Energy Corp | Novel purine derivative |
| AUPO912997A0 (en) | 1997-09-11 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| KR100613634B1 (en) * | 1997-11-28 | 2006-08-18 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | Novel heterocyclic compounds |
| JPH11180981A (en) * | 1997-12-19 | 1999-07-06 | Sumitomo Pharmaceut Co Ltd | Heterocyclic derivative |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| JP4189048B2 (en) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | Heterocyclic compounds |
| JP5420135B2 (en) | 2002-03-15 | 2014-02-19 | ウエイン・ステイト・ユニバーシテイ | Novel 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents |
| US7754728B2 (en) * | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
| EP1888587A1 (en) | 2005-05-04 | 2008-02-20 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
| DE102006053049A1 (en) | 2006-11-10 | 2008-05-15 | Daimler Ag | Storage compartment with a cover |
| BRPI0813952A2 (en) | 2007-06-29 | 2017-05-09 | Gilead Sciences Inc | purine derivatives and their use as modulators and bell-like receptor 7 |
| CN101239980B (en) | 2008-02-18 | 2011-06-22 | 靳广毅 | Immune receptor regulator couplet precursor, couplet and application thereof |
| WO2010077613A1 (en) | 2008-12-09 | 2010-07-08 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| AP3103A (en) * | 2009-10-22 | 2015-01-31 | Gilead Sciences Inc | Derivatives of purine or deazapurine useful for the treatment of (inter alia)viral infections |
| WO2011079016A1 (en) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| DK3190113T3 (en) | 2014-08-15 | 2021-06-07 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST |
| HUE045906T2 (en) * | 2015-05-08 | 2020-01-28 | Hoffmann La Roche | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection |
| ES2867849T3 (en) * | 2016-08-29 | 2021-10-21 | Hoffmann La Roche | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of viral infection |
-
2017
- 2017-08-28 ES ES17758527T patent/ES2867849T3/en active Active
- 2017-08-28 JP JP2019532184A patent/JP7013467B2/en active Active
- 2017-08-28 EP EP20207475.3A patent/EP3865482A1/en not_active Withdrawn
- 2017-08-28 AU AU2017320742A patent/AU2017320742B2/en active Active
- 2017-08-28 WO PCT/EP2017/071514 patent/WO2018041763A1/en active Application Filing
- 2017-08-28 PE PE2019000346A patent/PE20190476A1/en unknown
- 2017-08-28 RU RU2019107957A patent/RU2751349C2/en active
- 2017-08-28 KR KR1020197008982A patent/KR102459155B1/en active Application Filing
- 2017-08-28 MX MX2019002129A patent/MX2019002129A/en unknown
- 2017-08-28 SI SI201730728T patent/SI3504210T1/en unknown
- 2017-08-28 RS RS20210489A patent/RS61752B1/en unknown
- 2017-08-28 PT PT177585270T patent/PT3504210T/en unknown
- 2017-08-28 MA MA46038A patent/MA46038B1/en unknown
- 2017-08-28 TW TW106129087A patent/TWI671300B/en active
- 2017-08-28 SG SG10202010520SA patent/SG10202010520SA/en unknown
- 2017-08-28 CN CN201780052692.6A patent/CN109641904B/en active Active
- 2017-08-28 KR KR1020227036198A patent/KR20220147702A/en not_active Application Discontinuation
- 2017-08-28 UA UAA201903059A patent/UA124270C2/en unknown
- 2017-08-28 EP EP17758527.0A patent/EP3504210B1/en active Active
- 2017-08-28 CA CA3034148A patent/CA3034148A1/en active Pending
- 2017-08-28 DK DK17758527.0T patent/DK3504210T3/en active
- 2017-08-28 HU HUE17758527A patent/HUE053944T2/en unknown
- 2017-08-28 BR BR112019003519-2A patent/BR112019003519A2/en unknown
- 2017-08-28 IL IL293475A patent/IL293475A/en unknown
- 2017-08-28 MY MYPI2019001082A patent/MY197408A/en unknown
- 2017-08-28 SG SG11201901633WA patent/SG11201901633WA/en unknown
- 2017-08-28 PL PL17758527T patent/PL3504210T3/en unknown
- 2017-08-28 IL IL284255A patent/IL284255B/en unknown
- 2017-08-28 CR CR20190087A patent/CR20190087A/en unknown
- 2017-08-29 US US15/689,136 patent/US10233184B2/en active Active
-
2019
- 2019-01-29 US US16/260,744 patent/US10752630B2/en active Active
- 2019-01-30 CO CONC2019/0000932A patent/CO2019000932A2/en unknown
- 2019-02-07 IL IL264710A patent/IL264710B/en unknown
- 2019-02-21 MX MX2021006902A patent/MX2021006902A/en unknown
- 2019-02-26 CL CL2019000512A patent/CL2019000512A1/en unknown
- 2019-02-27 PH PH12019500432A patent/PH12019500432A1/en unknown
-
2020
- 2020-08-24 US US17/001,572 patent/US20200385387A1/en not_active Abandoned
-
2021
- 2021-04-19 HR HRP20210621TT patent/HRP20210621T1/en unknown
- 2021-06-24 AU AU2021204303A patent/AU2021204303B2/en active Active
-
2022
- 2022-01-17 JP JP2022004832A patent/JP7214900B2/en active Active
- 2022-06-30 AU AU2022204697A patent/AU2022204697A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901633WA (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201908569QA (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201810594RA (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201807051VA (en) | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto |